Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23240158 | 0.89 | ESR2 (0.45) | CNR1CYP1A2ESR2MAP4K4IDO1 | |
| SCHEMBL10388611 | 0.88 | CYP1A2 (0.46) | CNR1CYP1A2ESR2MAP4K4HSD11B1 | |
| SCHEMBL25616713 | 0.87 | CYP1A2 (0.52) | CNR1CYP1A2ESR2MAP4K4HSD11B1 | |
| SCHEMBL16574007 | 0.86 | ESR2 (0.52) | CNR1CYP1A2ESR2MAP4K4IDO1 | |
| SCHEMBL16574008 | 0.83 | CNR1 (0.46) | CNR1ESR2MAP4K4IDO1CYP3A4 | |
| SCHEMBL10452682 | 0.83 | CYP1A2 (0.58) | CNR1CYP1A2ESR2MAP4K4MAPT | |
| SCHEMBL16573982 | 0.80 | ALDH1A1 (0.50) | CNR1MAP4K4IDO1CYP3A4 | |
| SCHEMBL16574041 | 0.80 | TSHR (0.50) | CNR1ESR2MAP4K4CYP3A4MAPT | |
| SCHEMBL16574087 | 0.80 | MEN1 (0.43) | CNR1ESR2MAP4K4HSD11B1IDO1 | |
| SCHEMBL16574048 | 0.78 | RXRA (0.57) | CNR1MAP4K4CYP3A4SERPINE1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648333-B2 | Triarylamine compounds for use in organic light-emitting diodes | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
| EP-2491003-A2 | TRIARYLAMINE COMPOUNDS FOR ELECTRONIC APPLICATIONS | E. I. du Pont de Nemours and Company (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20110253985-A1 | TRIARYLAMINE COMPOUNDS FOR ELECTRONIC APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-10-20 | — | — | US | disclosed |
| WO-2011049953-A2 | TRIARYLAMINE COMPOUNDS FOR ELECTRONIC APPLICATIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253985-A1 | TRIARYLAMINE COMPOUNDS FOR ELECTRONIC APPLICATIONS | PNMT, COMT, TYR | CNR1 2774/4885CYP1A2 112/4885ESR2 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.